Table 1.
Demographic and clinical features, and biochemical parameters1 of biliary atresia patients and non-biliary atresia controls n (%)
| Variable | BA, n = 124 |
Non-BA, n = 140 |
|
| Other liver diseases2, n = 92 | Healthy, n = 48 | ||
| Age, mo | 2.9 (1.9-3.0) | 2.8 (2.0-3.2) | 3.4 (2.0-4.0) |
| Sex, male/female | 60/64 | 50/42 | 25/23 |
| METAVIR score | |||
| F0 | 4 (3.2) | NA | NA |
| F1 | 37 (29.8) | NA | NA |
| F2 | 24 (19.4) | NA | NA |
| F3 | 50 (40.3) | NA | NA |
| F4 | 9 (7.3) | NA | NA |
| ALT, U/L | 162.4 (104.3-204.6)a | 132.0 (70.5-247.5) | 28.1 (22.4-40.8) |
| AST, U/L | 190.5 (151.4-257.4)a | 195.9 (117.0-292.5) | 38.0 (26.0-52.3) |
| γ-GT, U/L | 716.0 (411.0-1142.5)a | 598.4 (189.5-1043.2) | 32.7 (23.4-46.3) |
| ALP, U/L | 406.8 (316.5-522.2)a | 517.0 (409.7-660.3) | 275.8 (189.0-345.6) |
| TBIL, μmol/L | 157.0 (126.5-184.0)a | 145.7 (107.1-196.5) | 6.5 (2.8-14.8) |
| DBIL, μmol/L | 130.5 (103.5-152.7)a | 110.1 (88.4-137.8) | 3.1 (1.0-4.9) |
Data are described as median (interquartile range: 25th-75th percentile). 1Reference intervals: ALT, 3-35 U/L; AST, 5-60 U/L; γ-GT, 13-57 U/L; ALP, 118-390 U/L; TBIL, 2-17 μmol/L; DBIL, 0-7 μmol/L;
Choledochal cysts, transient cholestasis of unknown origin, and neonatal intrahepatic cholestasis caused by citrin deficiency were included as disease controls.
P < 0.05 vs healthy controls. ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BA: Biliary atresia; DBIL: Direct bilirubin; FO-F4: Fibrosis scores 0-4; γ-GT: Gamma-glutamyl transpeptidase; NA: Not applicable; TBIL: Total bilirubin.